CARTESIAN THERAPEUTICS INC (RNAC)
Health Care · Cell therapy for autoimmune diseases · NASDAQ
mRNA-engineered cell therapy platform targeting autoimmune diseases with a Phase 3 program in myasthenia gravis.
What CARTESIAN THERAPEUTICS INC does
Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for autoimmune diseases. The company leverages a proprietary technology platform to introduce mRNA into cells that can be dosed repeatedly without requiring pre-treatment chemotherapy, administered in an outpatient setting. It is currently focused on developing therapies for conditions like generalized myasthenia gravis (MG), where it is conducting a Phase 3 clinical trial (AURORA).
Themes: ["cell therapy / cellular medicine","autoimmune disease treatment","myasthenia gravis","mRNA therapeutics","precision immune reset"]
Fundamentals
- Price$9.67 as of 2026-07-09 close
- Market cap$292M as of 2026-07-10
- 1-year return-29.8% as of 2026-07-09 close
- Net margin-8550.6% as of 2026-07-10
- ROE-3215.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-94.9% as of 2026-07-10
- Revenue CAGR (3y)-84.7% SEC XBRL
- Beta0.60 as of 2026-07-10
Key risks (from latest filing)
["Development-stage company with no approved products; significant risk of never achieving profitability or successfully commercializing product candidates","Clinical trial execution risks including ability to enroll patients, successfully complete trials, and obtain regulatory approvals; unproven approach to therapeutic intervention in cell therapy for autoimmune diseases","Manufacturing complexity and scalability challenges for patient-specific cell therapies; dependence on third parties including contract research organizations for clinical trial conduct"]
Competitors & peers
- Complement pathway inhibitors (Alexion/AstraZeneca)
- FcRn inhibitor manufacturers (Argenx - efgartigimod/Vyvgart; UCB - rozanolixizumab/Rystiggo)
- Other cell therapy developers in autoimmune space
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.